[A prospective pilot study of combined intra-operative radiotherapy for centrally located hepatocellular carcinomas]

Zhonghua Zhong Liu Za Zhi. 2017 Dec 23;39(12):926-930. doi: 10.3760/cma.j.issn.0253-3766.2017.12.009.
[Article in Chinese]

Abstract

Objective: To carry out a prospective cohort study of combined intra-operative radiotherapy for centrally located hepatocellular carcinomas (HCC) and to observe the safety and postoperative complications. Methods: A total of 79 patients with centrally located HCC who underwent hepatectomy were divided into two groups: experimental group (combined with targeted intra-operative radiotherapy, 32 cases) and control group (single surgical operation, 47 cases). Patients in the experimental group received intra-operative electron radiotherapy after tumor resection, while patients in the control group received to intra-operative electron radiotherapy.The haemorrhagia amount and operation time during the operation, intra-operative liver function and the recovery of liver and gastrointestinal tract of patients in these two groups were compared. Results: No postoperative 30-day mortality was observed in all of the patients. The average total operation time of patients in the experimental group was (319±76) min, significantly longer than (233±76) min of the control group (P<0.001). The average aspartate transaminase (AST) level of patients in the experimental group at postoperative day 1 was 562.5 U/L, significantly higher than 347.0 U/L of control group (P=0.031). However, the average prothrombin activity levels of patients in the experimental group at postoperative day 3 and day 7 were (68.3±17.9)% and (73.4±10.2)%, respectively, significantly lower than (78.9±15.9)% and (80.0±10.6)% of control group (both P<0.05). There were no significant differences of tumor volume, differentiation degree, satellite lesion, dorsal membrane invasion, microvascular invasion between these two groups (all P>0.05). There were no significant differences of hospital stay, ventilation time, the incidence of hepatic insufficiency, ascites, pleural effusion, infection, biliary fistula between these two groups (all P>0.05). There were no significant differences of alanine aminotransferase (ALT), albumin, total bilirubin between these two groups at postoperative day 1, 3, 5 and 7 (all of P>0.05). Conclusion: The resection of centrally located HCC combined with intra-operative radiotherapy may increase the total operation time, delay the early postoperative recovery of liver function, but it is still safe and feasible. Trial registration: National Cancer Centre /Cancer Hospital, Chinese Academy of Medical Sciences, ChiCTR-TRC-12002802.

目的: 探讨中央型肝细胞癌联合术中瘤床放疗的安全性,并观察近期并发症。 方法: 采用前瞻性队列研究方法将开腹切除肿瘤的79例中央型肝细胞癌患者分为研究组(联合术中瘤床放疗,32例)和对照组(单纯手术,47例)。研究组患者手术切除肿瘤后,瘤床行术中电子线放疗,对照组不作术中放疗。比较两组患者的术中出血量、手术时间、术后肝功能和胃肠功能的恢复情况以及手术并发症的发生情况。 结果: 两组患者术后30 d内均无死亡病例。研究组患者的总手术时间为(319±76)min,长于对照组[(233±76)min,P<0.001]。研究组患者术后第1天中位天门冬氨酸氨基转移酶水平为562.5 U/L,高于对照组(347.0 U/L,P=0.031)。研究组患者术后第3天、第7天平均凝血酶原活动度水平分别为(68.3±17.9)%和(73.4±10.2)%,均明显低于对照组[分别为(78.9±15.9)%和(80.0±10.6)%,均P<0.05]。两组患者的肿瘤大小、分化程度、有无卫星灶、被膜侵犯、微血管侵犯的差异均无统计学意义(均P>0.05)。两组患者的术后住院时间、肠道通气时间以及肝功能不全、大量腹水、胸腔积液、感染、胆瘘的发生率差异无统计学意义(均P>0.05)。两组患者术后第1、3、5、7天丙氨酸氨基转移酶、白蛋白、总胆红素的差异均无统计学意义(均P>0.05)。 结论: 中央型肝细胞癌联合术中瘤床放疗虽然延长了手术时间,延缓了术后肝功能的早期恢复,但仍是安全可行的。 临床试验注册: 中国医学科学院肿瘤研究所肿瘤医院,ChiCTR-TRC-12002802.

Keywords: Centrally located type; Combination; Hepatocellular carcinomas; Intra-operative radiotherapy; Surgical operation.

MeSH terms

  • Alanine Transaminase / blood
  • Ascites / epidemiology
  • Bilirubin / blood
  • Blood Loss, Surgical
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / radiotherapy*
  • Carcinoma, Hepatocellular / surgery*
  • Hepatectomy
  • Humans
  • Incidence
  • Intraoperative Care*
  • Length of Stay
  • Liver Neoplasms / pathology
  • Liver Neoplasms / radiotherapy*
  • Liver Neoplasms / surgery*
  • Operative Time
  • Pilot Projects
  • Prospective Studies

Substances

  • Alanine Transaminase
  • Bilirubin